TOP > 外国特許検索 > INHIBITOR OF LYMPH NODE METASTASIS OF CANCER

INHIBITOR OF LYMPH NODE METASTASIS OF CANCER UPDATE

外国特許コード F150008102
整理番号 S2013-0427-C0
掲載日 2015年2月5日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2014JP051797
国際公開番号 WO 2014119556
国際出願日 平成26年1月28日(2014.1.28)
国際公開日 平成26年8月7日(2014.8.7)
優先権データ
  • 特願2013-015008 (2013.1.30) JP
発明の名称 (英語) INHIBITOR OF LYMPH NODE METASTASIS OF CANCER UPDATE
発明の概要(英語) The present invention addresses the problem of providing an inhibitor of lymph node metastasis of cancer which can be applied to a broad range of patients and can be used in combination with chemotherapy (anticancer drug treatment), radiation therapy, etc. The present invention provides an inhibitor of lymph node metastasis of cancer having C-reactive protein as an active ingredient. The inhibitor of lymph node metastasis can be used in combination with chemotherapy (anticancer drug treatment), radiation therapy, etc.
従来技術、競合技術の概要(英語) BACKGROUND ART
Cancer metastasis, cancer cells where it occurred (hereinafter, sometimes referred to as HCCs) away from, via the blood vessel or lymphatic vessels, lymph nodes or the liver, other organs such as lungs and fixed on moving, where the tumor to grow again (metastatic tumors) refers to a form. According to the cause deaths due to cancer in said to be almost this transition.
The development of cancer modes, hematogenous metastasis, lymph metastatic line (hereinafter, sometimes referred to as lymph node metastasis) types 3 and disseminated metastases. Hematogenous metastasis, blood capillary or a vein HCCs in the vicinity of the entrance of the cancer cells, liver through the blood stream, lungs, brain, organs such as bone, so-called rich flow of blood and delivered to the site, where the growth refers to. In this case, on a stream of the systemic blood expands to a cancer cell, such as surgery or radiation in the topical treatment is not performed, chemotherapeutic (anti-cancer agent treatment) mainly for the treatment. Lymph node metastasis, cancer cells into the lymph flow, present in the lymph nodes through lymphatic vessels reaches the systemic, which refers to grow in. Lymph node metastases, occur close to the lymph nodes from HCCs, gradually distant lymph nodes is generally spread. Therefore, only HCCs transition occurred close to the lymph nodes in the case, and the surrounding lymph nodes HCCs (lymph node dissection) surgical resection, radiation therapy or the same site can be cured high. However, metastasis to lymph nodes far away from the primary case has abroadened, systemic organ metastasis cancer cells already in the same manner as a flaring, chemotherapeutic (anti-cancer agent treatment) and the main treatment methods. Disseminated metastasis, intraperitoneal cavity and in the human body that the pleural space, peritoneum and the thoracic cavity, the surface of the intraperitoneal organs, such as if one were seeded with cancer cells disseminated metastatic tumor-forming means. 3 In this way is significantly different from the one manner of cancer metastasis, as well as the mechanism it, promoting factor, different factors can also be suppressed. For this reason these anti-cancer treatment to control the manner in which the target has been developed as each transition, are implemented.
The degree of advancement of cancer, mainly International Union gun pair TMN is proposed (UICC) classification of the classified I-IV. This classification can be, as determined from the next one element 3. T: Tumor, i.e. for tumor (lumps), tumor free (making an not made) from the level of T0, the size of the gun by the depth of the infiltration, the levels of any of T1 - T4 is determined. The level of this T1 - T4 is determined for each organ. N: Lymph nodes, i.e. for lymph nodes, of "without lymph node metastasis" from the level of N0, depending on the degree of lymph node metastasis, determined whether all levels of N1 - N4. The N1 - N4 for each organ determined by the level of, generally a larger number of lymph node metastasis, more distant lymph node metastasis number N is increased. M: Metastasis, i.e. for distant metastases, and M0 of "without distant metastases", 2 "and distant metastases" is deemed to be of the type of M1. This determination is also applies to any organ. It should be noted that, when it is determined that the M1, and the degree of advancement of all stage IV cancer. If the cancer is a remote organ metastasis already spread and systemic, chemotherapeutic (anti-cancer agent treatment) but the main treatment methods, little to make the radical cure. On the other hand, in the case it is determined that the M0, the level of the N is classified into I-IV. For example, it is determined that the lymph node metastasis if the level N1, the gun is close to the lymph nodes HCCs HCCs and remains on the small number of, surgery or radiation in the site in the topical treatment in many can heal.
The classification of cancer severity as shown, the transition of the gun which is especially important in lymph node metastasis, which influences the prognosis of the patient. Actually, the present inventors (early cancer) esophageal cancer in a patient superficial presence of lymph node metastasis and 5 - year survival rate was examined in the context of, not of lymph node metastasis in a cancer patient who is at an early stage of the 5 - year survival rate as opposed to the 92%, 1 of 67% patients with lymph node metastasis, 2 of 64% patients with lymph node metastasis and also, the lymph node metastasis 1 only one sharp decrease in the 5 - year survival rate was confirmed. In addition, in patients with cancer progression, if there is no lymph node metastasis and 5 - year survival rate is 86%, 1 gullet having a superficial lymph node metastasis of cancer was confirmed to be higher than the patient. Therefore, in patients diagnosed with cancer, lymph node metastasis can be suppressed, improving the rate of a complete cure of cancer becomes possible.
To lymph node metastasis of a cancer, characterized in that the therapeutically as an agent, as an active ingredient component of bacteria, for cancer immunotherapy agent monotherapy has been developed (patent document 1). However, this cancer immunotherapy agent, IFN-γ in the blood and an increase in CD28 positive lymphocyte group strength index only have the ability to immune response and so the patient. In addition, monotherapy for effect is not obtained not, chemotherapeutic (anti-cancer agent treatment), strong promoters such as the radiation therapy treatment in combination with anti-cancer effect cannot be.
The inventors of the present invention, chemotherapeutic (anti-cancer agent treatment), radiation therapy and the like can be used together to obtain the lymph node metastasis suppressing agent, C-reactive protein (C-reactive protein; CRP (hereinafter, sometimes referred to as CRP) ) is focused on. Acute or chronic inflammation is C-reactive protein when the protein is produced in the liver, may develop various solid cancer have been reported to be involved. For example, breast cancer lung metastases Modified form C-reactive protein is inhibition action have been reported (non-patent document 1). In addition, liposomes encapsulating C-reactive protein is a malignant fibrous sarcoma lung metastases inhibition action (non-patent document 2), liver metastasis of colon cancer inhibition action (non-patent document 3) are also reported. However these reported previously and is limited in both hematogenous metastatic spread, C-reactive protein as known effect on the lymph node metastasis was not (non-patent document 1-3, Patent Document 2-5).
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • NATIONAL UNIVERSITY CORPORATION AKITA UNIVERSITY
  • 発明者(英語)
  • MOTOYAMA, Satoru
  • SASAKI, Tomohiko
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LT LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN TD TG
ライセンスをご希望の方、特許の内容に興味を持たれた方は、下記「問合せ先」まで直接お問い合わせください。

PAGE TOP

close
close
close
close
close
close